Beurs.nl
Uitgebreid zoeken
monitor iconMarkt Monitor
  • AEX -6,04 913,22 -0,66%
  • DE40 0,00 22.999,15 0,00%
  • US500^ -17,39 5.646,97 -0,31%
  • US30^ -137,00 41.838,60 -0,33%
  • EUR/USD 0,00 1,0840 -0,16%
  • WTI -0,58 67,75 -0,85%
  • Gold spot -14,78 3.031,15 -0,49%

Remdesivir

136 Posts
Pagina: «« 1 2 3 4 5 6 7 »» | Laatste | Omlaag ↓
  1. forum rang 5 Endless 13 juli 2020 11:00

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 21 mrt 2025

    • Aanbevelingen

      Ontvangen: 2869

      Gegeven: 2239

    •    Aantal posts: 6.057

    Third of S.Korea COVID-19 patients improve with remdesivir

    Jul. 13, 2020 4:50 AM ET|About: Gilead Sciences, Inc. (GILD)|By: Yoel Minkoff, SA News Editor
    The Korea Centers for Disease Control and Prevention is reporting results from a first group of 27 patients given Gilead Sciences' (NASDAQ:GILD) remdesivir in different hospitals.

    One in three South Korean patients seriously ill with COVID-19 showed an improvement in their condition, though more research is needed to determine if the improvement was attributable to the drug or other factors like immunity and other therapies.

    Several other countries have added the drug to the list of treatment for the disease caused by the coronavirus.

    On Friday, Gilead said an analysis showed remdesivir helped reduce the risk of death in severely ill COVID-19 patients but cautioned that rigorous clinical trials were needed to confirm the benefit.
  3. [verwijderd] 14 juli 2020 09:21

    • [verwijderd]

      Lid sinds: 01 jan 0001

      Laatste bezoek: 01 jan 0001

    • Aanbevelingen

      Ontvangen: 0

      Gegeven: 0

    •    Aantal posts: 0

    Nou Endless als die 62% verbetering blijft staan dan moet dit iets met de koers doen. Gisteren was er ook een behoorlijke stijging maar misschien wel op dit nieuws, ik weet het niet.
  4. forum rang 5 Endless 20 juli 2020 14:39

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 21 mrt 2025

    • Aanbevelingen

      Ontvangen: 2869

      Gegeven: 2239

    •    Aantal posts: 6.057

    Innovation Pharma's Brilacidin shows encouraging anti-SARS-CoV-2 action in preclinical testing

    Jul. 20, 2020 7:52 AM ET|About: Innovation Pharmaceuti... (IPIX)|By: Douglas W. House, SA News Editor
    Innovation Pharmaceuticals (OTCQB:IPIX) announces new data from ongoing lab testing of Brilacidin for COVID-19.

    In a human lung epithelial cell line, recently released data showed that Brilacidin reduced the coronavirus viral load by 95% and 97%, respectively, at two concentrations tested.

    The new results, based on the same assay method, demonstrated that a concentration 50% below the lower of the two previously tested concentrations of Brilacidin inhibited the coronavirus by ~90%.

    The company cites a Nature-published article that showed Gilead Sciences' (NASDAQ:GILD) remdesivir achieved 50% inhibition of SARS-CoV-2 in a time-of-addition experiment in animal cells.

    The data will be submitted for publication.

    A Phase 2 clinical trial should launch in Q4.
  6. forum rang 5 Endless 21 juli 2020 14:48

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 21 mrt 2025

    • Aanbevelingen

      Ontvangen: 2869

      Gegeven: 2239

    •    Aantal posts: 6.057

    quote:

    Ooievaar schreef op 14 juli 2020 09:21:

    Nou Endless als die 62% verbetering blijft staan dan moet dit iets met de koers doen. Gisteren was er ook een behoorlijke stijging maar misschien wel op dit nieuws, ik weet het niet.
    Ze zijn goed bezig (zie tweet) niet alles draait om remdesivir
  10. forum rang 5 Endless 2 augustus 2020 22:48

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 21 mrt 2025

    • Aanbevelingen

      Ontvangen: 2869

      Gegeven: 2239

    •    Aantal posts: 6.057

    Gilead Sciences (GILD:UN)
    69.51 2.82 (3.89%)
    As of: 08/02/20 4:43:57 pm
    (delayed at least 15 minutes)
    10. May
    24. May
    8. Jun
    20. Jun
    6. Jul
    20. Jul
    2. Aug
    65
    70
    75
    80
    85
    90
    Chart Type - 3month
    See Full Stock Page »
    Health Canada has authorized the use of Gilead Sciences Canada Inc.’s remdesivir drug to treat people with severe COVID-19 symptoms on Tuesday, making this the first drug the regulator has approved to treat the virus.
    The use of remdesivir is authorized only under certain conditions, Health Canada said. It has been approved for use in adults and adolescents aged 12 years or older.
    Health Canada’s other conditions include that the manufacturer ensures the continued safety, efficacy, and quality of the drug. The regulator said it will closely monitor how remdesivir is prescribed to patients and will take action if any concerns arise.
    "We appreciate Health Canada's expedited review of Veklury (the brand name for remdesivir) in recognition of the urgent need to treat COVID-19 patients in Canada," Gilead Sciences Canada General Manager Melissa Koomey said in a release Tuesday. "We are thankful for their collaboration and leadership, as we together work to respond to this public health emergency."
    The drug has been given emergency or conditional authorization in some other countries including the United States, Japan, Europe and Australia.
    In Canada, some COVID-19 patients have already been treated with remdesivir under the regulator's ?Special Access Program.
  17. forum rang 5 Endless 10 augustus 2020 19:34

    • Endless

      Lid sinds: 06 jan 2015

      Laatste bezoek: 21 mrt 2025

    • Aanbevelingen

      Ontvangen: 2869

      Gegeven: 2239

    •    Aantal posts: 6.057

    Gilead Sciences files U.S. application for remdesivir for COVID-19

    Aug. 10, 2020 12:13 PM ET|About: Gilead Sciences, Inc. (GILD)|By: Douglas W. House, SA News Editor
    Gilead Sciences (GILD -1.7%) has completed its rolling marketing application to the FDA seeking full approval of Veklury (remdesivir) for the treatment of severely ill hospitalized COVID-19 patients. It initiated the process on April 8.

    The FDA approved the emergency use of the antiviral for these patients on May 1. It remains the only medicine to receive the nod in the U.S. to date. It is also available in Europe, Japan, India, Australia and Canada.
136 Posts
Pagina: «« 1 2 3 4 5 6 7 »» | Laatste |Omhoog ↑

Neem deel aan de discussie

Word nu gratis lid van Beurs.nl

Al abonnee? Log in

Direct naar Forum

Zoek alfabetisch op forum

  1. A
  2. B
  3. C
  4. D
  5. E
  6. F
  7. G
  8. H
  9. I
  10. J
  11. K
  12. L
  13. M
  14. N
  15. O
  16. P
  17. Q
  18. R
  19. S
  20. T
  21. U
  22. V
  23. W
  24. X
  25. Y
  26. Z
Forum # Topics # Posts
Aalberts 466 7.104
AB InBev 2 5.531
Abionyx Pharma 2 29
Ablynx 43 13.356
ABN AMRO 1.582 52.058
ABO-Group 1 22
Acacia Pharma 9 24.692
Accell Group 151 4.132
Accentis 2 267
Accsys Technologies 23 10.825
ACCSYS TECHNOLOGIES PLC 218 11.686
Ackermans & van Haaren 1 192
Adecco 1 1
ADMA Biologics 1 34
Adomos 1 126
AdUX 2 457
Adyen 14 17.802
Aedifica 3 925
Aegon 3.258 323.034
AFC Ajax 538 7.088
Affimed NV 2 6.305
ageas 5.844 109.901
Agfa-Gevaert 14 2.062
Ahold 3.538 74.348
Air France - KLM 1.025 35.263
AIRBUS 1 12
Airspray 511 1.258
Akka Technologies 1 18
AkzoNobel 467 13.049
Alfen 16 25.175
Allfunds Group 4 1.516
Almunda Professionals (vh Novisource) 651 4.251
Alpha Pro Tech 1 17
Alphabet Inc. 1 418
Altice 106 51.198
Alumexx ((Voorheen Phelix (voorheen Inverko)) 8.486 114.826
AM 228 684
Amarin Corporation 1 133
Amerikaanse aandelen 3.837 243.726
AMG 971 134.217
AMS 3 73
Amsterdam Commodities 305 6.743
AMT Holding 199 7.047
Anavex Life Sciences Corp 2 495
Antonov 22.632 153.605
Aperam 92 15.047
Apollo Alternative Assets 1 17
Apple 5 384
Arcadis 252 8.798
Arcelor Mittal 2.034 320.934
Archos 1 1
Arcona Property Fund 1 286
arGEN-X 17 10.350
Aroundtown SA 1 221
Arrowhead Research 5 9.750
Ascencio 1 28
ASIT biotech 2 697
ASMI 4.108 39.594
ASML 1.766 109.773
ASR Nederland 21 4.507
ATAI Life Sciences 1 7
Atenor Group 1 522
Athlon Group 121 176
Atrium European Real Estate 2 199
Auplata 1 55
Avantium 32 13.828
Axsome Therapeutics 1 177
Azelis Group 1 66
Azerion 7 3.442